KR20110063479A - 치환된 트리아졸로-피리다진 유도체 - Google Patents

치환된 트리아졸로-피리다진 유도체 Download PDF

Info

Publication number
KR20110063479A
KR20110063479A KR20117006632A KR20117006632A KR20110063479A KR 20110063479 A KR20110063479 A KR 20110063479A KR 20117006632 A KR20117006632 A KR 20117006632A KR 20117006632 A KR20117006632 A KR 20117006632A KR 20110063479 A KR20110063479 A KR 20110063479A
Authority
KR
South Korea
Prior art keywords
compound
composition
deuterium
compounds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20117006632A
Other languages
English (en)
Korean (ko)
Inventor
스코트 하베슨
Original Assignee
콘서트 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘서트 파마슈티컬즈, 인크. filed Critical 콘서트 파마슈티컬즈, 인크.
Publication of KR20110063479A publication Critical patent/KR20110063479A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR20117006632A 2008-08-29 2009-08-28 치환된 트리아졸로-피리다진 유도체 Ceased KR20110063479A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9329308P 2008-08-29 2008-08-29
US61/093,293 2008-08-29

Publications (1)

Publication Number Publication Date
KR20110063479A true KR20110063479A (ko) 2011-06-10

Family

ID=41721962

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20117006632A Ceased KR20110063479A (ko) 2008-08-29 2009-08-28 치환된 트리아졸로-피리다진 유도체

Country Status (17)

Country Link
US (4) US8003646B2 (https=)
EP (2) EP2328414B1 (https=)
JP (3) JP5183808B2 (https=)
KR (1) KR20110063479A (https=)
CN (2) CN104098578A (https=)
AU (1) AU2009285533B2 (https=)
BR (1) BRPI0912928A2 (https=)
CA (1) CA2735549A1 (https=)
DK (1) DK2328414T3 (https=)
EA (1) EA020071B1 (https=)
ES (1) ES2451542T3 (https=)
HR (1) HRP20140195T1 (https=)
MX (1) MX2011002278A (https=)
PL (1) PL2328414T3 (https=)
PT (1) PT2328414E (https=)
WO (1) WO2010025407A1 (https=)
ZA (1) ZA201102123B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104098578A (zh) * 2008-08-29 2014-10-15 康瑟特制药公司 取代的三唑并哒嗪衍生物
WO2010037194A1 (pt) 2008-10-03 2010-04-08 Instituto Alberto Luiz De Coimbra De Pós Graduação E Pesquisa De Engenharia - Coppe/Ufrj Dispositivo para remoção de fragmentos metálicos e elementos metálicos do interior de canáis radiculares de dentes e processo para remoção dos mesmos
JP2012531419A (ja) 2009-06-23 2012-12-10 コンサート ファーマシューティカルズ インコーポレイテッド Ｇａｂａ−ａ受容体修飾物質としての重水素修飾されたトリアゾロピリダジン誘導体
JP2014530870A (ja) * 2011-10-20 2014-11-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
HK1201270A1 (en) 2012-01-11 2015-08-28 Bayer Intellectual Property Gmbh Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2013170242A1 (en) * 2012-05-11 2013-11-14 Concert Pharmaceuticals, Inc. Form 2 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
US20150158870A1 (en) * 2012-05-11 2015-06-11 Concert Pharmaceuticals Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2015052173A1 (en) 2013-10-10 2015-04-16 Basf Se Tetrazole and triazole compounds and their use as herbicides
WO2015052178A1 (en) 2013-10-10 2015-04-16 Basf Se 1,2,5-oxadiazole compounds and their use as herbicides
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
KR20160117596A (ko) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
CN104474549A (zh) * 2014-11-24 2015-04-01 王寿世 异丙酚和gabaa受体拮抗剂在制备麻醉药物中的用途
CN104353078B (zh) * 2014-11-24 2017-10-24 王寿世 一种麻醉用药物组合物
US10026332B1 (en) 2017-04-10 2018-07-17 Jasmine Gupta Method to deliver contextual educational information utilizing smart wearables
CA3132810A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of fybromyalgia
EP4511025A4 (en) * 2022-04-20 2026-04-15 Engrail Therapeutics Inc GABAa receptor modulator salts, particles, and their uses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321162D0 (en) 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
KR20000029548A (ko) * 1996-07-25 2000-05-25 더블유. 지. 콜 가바수용체에대한리간드로서의치환된트리아졸로-피리다진유도체
HUP0100575A3 (en) * 1998-01-21 2003-03-28 Merck Sharp & Dohme Ltd Hoddes Triazolo-pyridazine derivatives as ligands for gaba receptors
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ATE284403T1 (de) * 1999-01-27 2004-12-15 Merck Sharp & Dohme Triazolopyridazinderivate als liganden für gaba- rezeptoren
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2004048980A1 (en) * 2002-11-28 2004-06-10 Neurosearch A/S Method for screening for compounds as potential sedatives or anxiolytics
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010501572A (ja) * 2006-08-22 2010-01-21 コンサート ファーマシューティカルズ インコーポレイテッド ４−アミノキナゾリン誘導体およびその使用方法
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
AU2008232425A1 (en) * 2007-04-02 2008-10-09 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
CN104098578A (zh) * 2008-08-29 2014-10-15 康瑟特制药公司 取代的三唑并哒嗪衍生物

Also Published As

Publication number Publication date
BRPI0912928A2 (pt) 2015-08-04
DK2328414T3 (en) 2014-03-10
JP5183808B2 (ja) 2013-04-17
EA201100409A1 (ru) 2011-10-31
HRP20140195T1 (hr) 2014-04-11
US20100056529A1 (en) 2010-03-04
JP2012501346A (ja) 2012-01-19
ZA201102123B (en) 2011-12-28
CN102176826B (zh) 2014-08-20
US8921366B2 (en) 2014-12-30
JP2014058518A (ja) 2014-04-03
AU2009285533A2 (en) 2011-04-21
US20130225590A1 (en) 2013-08-29
EP2328414A4 (en) 2011-11-16
US8399467B2 (en) 2013-03-19
US20120004236A1 (en) 2012-01-05
PL2328414T3 (pl) 2014-05-30
CA2735549A1 (en) 2010-03-04
JP5373982B2 (ja) 2013-12-18
US8003646B2 (en) 2011-08-23
PT2328414E (pt) 2014-03-17
ES2451542T3 (es) 2014-03-27
EP2716158A1 (en) 2014-04-09
WO2010025407A1 (en) 2010-03-04
EA020071B1 (ru) 2014-08-29
AU2009285533A1 (en) 2010-03-04
AU2009285533B2 (en) 2014-02-13
MX2011002278A (es) 2011-04-14
EP2328414B1 (en) 2013-12-11
EP2328414A1 (en) 2011-06-08
CN102176826A (zh) 2011-09-07
CN104098578A (zh) 2014-10-15
JP2013100322A (ja) 2013-05-23
US20150111895A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
KR20110063479A (ko) 치환된 트리아졸로-피리다진 유도체
US20190308976A1 (en) Deuterated derivatives of ruxolitinib
JP6261580B2 (ja) 重水素化イブルチニブ
US20110082147A1 (en) Substituted imidazotriazines
US20090005394A1 (en) Endothelin receptor antagonists
US10357499B2 (en) Substituted triazolobenzodiazepines
WO2009128947A1 (en) Piperazine derivatives
US8557815B2 (en) Substituted triazolophthalazine derivatives
KR102433283B1 (ko) 룩소리티닙의 중수소화된 유도체
US20090197899A1 (en) 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
WO2009099620A1 (en) 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
WO2010002451A1 (en) Naphthyridin derivatives
AU2014202485A1 (en) Substituted triazolo-pyridazine derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140827

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160321

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160830

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160321

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I